Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19
Complement, a critical defence against pathogens, has been implicated as a driver of pathology in COVID-19. Complement activation products are detected in plasma and tissues and complement blockade considered for therapy. To delineate roles of complement in immunopathogenesis, we undertook the large...
Main Authors: | Siggins, M, Davies, K, Fellows, R, Thwaites, R, Baillie, K, Semple, M, Openshaw, P, Zelek, W, Harris, CL, Morgan, BP, Dunning, W |
---|---|
Outros Autores: | The ISARIC4C Investigators |
Formato: | Journal article |
Idioma: | English |
Publicado em: |
Wiley
2022
|
Registos relacionados
-
Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species
Por: Wioleta M. Zelek, et al.
Publicado em: (2020-12-01) -
Terminal complement pathway activation drives synaptic loss in Alzheimer’s disease models
Por: Sarah M. Carpanini, et al.
Publicado em: (2022-07-01) -
Dysregulation of complement system in HELLP syndrome
Por: Shi Chen, et al.
Publicado em: (2021-10-01) -
Measuring Total Classical Pathway and Activities of Individual Components of the Mouse Complement Pathway
Por: Wioleta Zelek
Publicado em: (2021-10-01) -
Chronic complement dysregulation drives neuroinflammation after traumatic brain injury: a transcriptomic study
Por: Amer Toutonji, et al.
Publicado em: (2021-07-01)